Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
February 07 2017 - 8:00AM
Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical
company advancing novel, adeno-associated virus (AAV) gene
therapies targeting the liver, a key organ for human metabolism,
today announced the election of John A. Hohneker, M.D., Executive
Vice President, Head of Research and Development of FORMA
Therapeutics Inc., to Dimension’s Board of Directors (the “Board”).
Dr. Hohneker brings over 25 years’ global experience in
pharmaceutical drug development across diverse therapeutic areas to
address substantial unmet needs. His election to the company’s
Board is effective immediately.
“John is a highly accomplished leader in the biopharma industry,
and we are pleased to welcome him to Dimension’s Board,” said Dr.
Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension.
“John offers broad experience developing therapeutics from
preclinical testing through health authority approval across
multiple therapeutic areas, including 17 drug launches. We expect
his expertise will contribute greatly to the continued progress of
our clinical and preclinical stage pipeline.”
“John has built high-performing teams and successfully developed
multiple ground-breaking medicines that have had a profound impact
on global human health,” stated Rishi Gupta, JD, Private Equity
Partner at OrbiMed and Chairman of Dimension’s Board. “His
perspectives and insight will have an important impact as
Dimension’s novel product portfolio further progresses into and
through the clinic.”
Dr. Hohneker stated, “Dimension is developing therapies with the
potential to transform the treatment of rare, metabolic diseases
associated with the liver, which often have devastating outcomes
for patients and their families. I look forward to contributing to
the company’s advancement of these promising product candidates in
the clinic.”
Most recently, Dr. Hohneker has guided FORMA’s transition from
the discovery stage to a company with programs in clinical trials.
Prior to this, he held leadership positions at Novartis, including
as Senior Vice President and Global Head of Development, Immunology
and Dermatology, in which role he was responsible for the global
development of the company’s immunology, rheumatology, and
dermatology product pipelines. During his tenure at Novartis, Dr.
Hohneker played a key role in the development, approval, and/or
commercialization of products including Cosentyx®, Xolair®,
Ilaris®, Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®.
Previously, Dr. Hohneker held various roles of increasing
responsibility at Glaxo Wellcome and Burroughs Wellcome, including
as Worldwide Therapeutic Head, Director, Oncology Clinical
Development. Dr. Hohneker received his bachelor’s degree in
chemistry from Gettysburg College and M.D. degree from the
University of Medicine and Dentistry of New Jersey, Rutgers Medical
School (Robert Wood Johnson Medical School). He completed his
internship and residency in internal medicine and his fellowship in
medical oncology, all at the University of North Carolina
Hospitals.
About Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in
discovering and developing new therapeutic products for people
living with devastating rare and metabolic diseases associated with
the liver, based on the most advanced, mammalian adeno-associated
virus (AAV) gene delivery technology. Dimension is actively
progressing its broad pipeline, which features programs addressing
unmet needs for patients suffering from inherited metabolic
diseases, including OTC deficiency, GSDIa, citrullinemia type 1,
PKU, Wilson disease, a collaboration with Bayer in hemophilia A,
and a wholly owned clinical program in hemophilia B. Dimension has
two phase 1/2 clinical trials for the treatment of hemophilia B and
OTC deficiency. The company targets diseases with readily
identifiable patient populations, highly predictive preclinical
models, and well-described, and often clinically validated,
biomarkers. Founded in 2013, Dimension maintains headquarters in
Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
development, preclinical and clinical results, and the continued
progress of Dimension's portfolio and programs, including the
initiation, timing, scope, or likelihood of regulatory filings and
approvals, and our ability to develop and advance product
candidates into, and successfully complete, clinical studies. All
such forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
the risks that Dimension’s product candidates, including its
candidates, DTX101 and DTX301, will not successfully be developed
or commercialized in the times indicated or at all; and the risks
described under the caption "Risk Factors" in Dimension
Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended
September 30, 2016, which is on file with the Securities and
Exchange Commission, as well as other risks detailed in Dimension
Therapeutics’ additional filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Dimension Therapeutics undertakes no duty to
update this information unless required by law.
Contacts:
Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com
Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024